EURURO Vol. 71 No. 5

700 844

Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at
References
[1] Powell IJ, Bollig-Fischer A. Minireview: the molecular and genomic
basis for prostate cancer health disparities. Mol Endocrinol
2013;27:879–91.
[2] Tan DSW, Mok TSK, Rebbeck TR. Cancer genomics: diversity and
disparity across ethnicity and geography. J Clin Oncol 2016;34:
91–101. .
[3] Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2
and ETS transcription factor genes in prostate cancer. Science
2005;310:644–8. .
[4] The Cancer Genome Atlas Research Network. The molecular taxon-
omy of primary prostate cancer. Cell 2015;163:1011–25.
[5] Pettersson A, Graff RE, Bauer SR, et al. The TMPRSS2:ERG rearrange-
ment:ERG expression, and prostate cancer outcomes: a cohort study
and meta-analysis. Cancer Epidemiol Biomarkers Prev 2012;21:
1497–509.
[6] Ahearn TU, Pettersson A, Ebot EM, et al. A prospective investigation
of PTEN loss and ERG expression in lethal prostate cancer. J Natl
Cancer Inst 2016;108:1–9. .
[7] Magi-Galluzzi C, Tsusuki T, Elson P, et al. TMPRSS2-ERG gene fusion
prevalence and class are significantly different in prostate cancer of
Caucasian, African-American and Japanese patients. Prostate
2011;71:489–97.
[8] Khani F, Mosquera JM, Park K, et al. Evidence for molecular differ-
ences in prostate cancer between African American and Caucasian
men. Clin Cancer Res 2014;20:4925–34.
.
[9]
[10]
.
E U R O P E A N U R O L O G Y 7 1 ( 2 0 1 7 ) 6 9 7 – 7 0 0 700